🧪 Beta — BiohacksAI is under active development. Data and features may change.
B
BiohacksAI
Evidence-Based Biohacking
BetaPatent Pending

Canagliflozin vs N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide

Mechanistic comparison of Canagliflozin and N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide [Supplementary Concept] based on molecular target overlap from BindingDB and ChEMBL binding affinity data.

5
Shared Targets
24%
Jaccard Similarity
19%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.

Evidence Comparison

Canagliflozin
—
Evidence Score
295
PubMed Studies
View full profile →
N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide [Supplementary Concept]
—
Evidence Score
—
PubMed Studies
View full profile →

Target Overlap

Canagliflozin and N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide share 5 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.238 means 24% of the combined target set is bound by both compounds. The IDF-weighted score of 0.192 accounts for non-specific binding to metabolic enzymes.

Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.

Frequently Asked Questions

What do Canagliflozin and N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide have in common?
Canagliflozin and N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide share 5 molecular targets with a Jaccard similarity of 24%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Canagliflozin and N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide be combined?
Canagliflozin and N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide share 5 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Canagliflozin or N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide?
Both Canagliflozin and N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide have substantial PubMed research. View their individual profiles for full evidence scores.

Related Comparisons

Similar to Canagliflozin

Canagliflozin vs sergliflozin2 targetsCanagliflozin vs canagliflozin2 targetsCanagliflozin vs ertugliflozin2 targetsCanagliflozin vs sergliflozin2 targetsCanagliflozin vs ipragliflozin2 targets

Similar to N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide

N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide vs casin5 targetsN-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide vs cinacalcet8 targetsN-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide vs darapladib7 targetsN-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide vs cyclohexyl4 targetsN-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide vs Fluvastatin4 targets
View full Canagliflozin profile →View full N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide profile →Browse all substances →